Hormone Therapy: Improving Therapy Decisions and Monitoring Alexandre R. Zlotta, Per-Anders Abrahamsson, Bertrand Tombal, Richard Berges, Frans Debruyne  European Urology Supplements  Volume 5, Issue 3, Pages 369-376 (April 2006) DOI: 10.1016/j.eursup.2006.01.002 Copyright © 2006 Elsevier B.V. Terms and Conditions

Fig. 1 (A) Almost 80% of the attendees indicated that the ability to achieve castrate levels of testosterone is an important factor to decide which is the preferred LHRH agonist. (B) The ability to suppress testosterone levels is the most important indicator to choose a specific LHRH agonist formulation. European Urology Supplements 2006 5, 369-376DOI: (10.1016/j.eursup.2006.01.002) Copyright © 2006 Elsevier B.V. Terms and Conditions

Fig. 2 (A) Over 80% of the attendees indicated that achieving “the lowest possible level of testosterone” is the best. (B) Over 80% of the attendees indicated that ≤20ng/dl is the preferred castrate testosterone level that needs to be achieved after LHRH agonist therapy. European Urology Supplements 2006 5, 369-376DOI: (10.1016/j.eursup.2006.01.002) Copyright © 2006 Elsevier B.V. Terms and Conditions

Fig. 3 Both the 1-mo and the 3-mo formulations of Eligard® are able to achieve testosterone castrate levels far below 20ng/dl [46,47]. *: Achieved after 6 mo of Eligard®. European Urology Supplements 2006 5, 369-376DOI: (10.1016/j.eursup.2006.01.002) Copyright © 2006 Elsevier B.V. Terms and Conditions